|
Thermo Fisher Scientific Inc. (TMO) DCF Valoración
US | Healthcare | Medical - Diagnostics & Research | NYSE
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Thermo Fisher Scientific Inc. (TMO) Bundle
¡Evalúe las perspectivas financieras de Thermo Fisher Scientific Inc. (TMO) como un experto! Esta calculadora DCF (TMO) le proporciona finanzas precarias, al tiempo que le permite la libertad de modificar el crecimiento de los ingresos, WACC, los márgenes y otros supuestos esenciales para alinearse con sus predicciones.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25,542.0 | 32,218.0 | 39,211.0 | 44,915.0 | 42,857.0 | 49,050.6 | 56,139.4 | 64,252.6 | 73,538.3 | 84,166.0 |
| Revenue Growth, % | 0 | 26.14 | 21.71 | 14.55 | -4.58 | 14.45 | 14.45 | 14.45 | 14.45 | 14.45 |
| EBITDA | 6,463.0 | 10,192.0 | 12,964.0 | 11,941.0 | 11,195.0 | 13,999.8 | 16,023.0 | 18,338.7 | 20,988.9 | 24,022.2 |
| EBITDA, % | 25.3 | 31.63 | 33.06 | 26.59 | 26.12 | 28.54 | 28.54 | 28.54 | 28.54 | 28.54 |
| Depreciation | 2,277.0 | 2,325.0 | 2,592.0 | 3,381.0 | 3,406.0 | 3,749.1 | 4,290.9 | 4,911.0 | 5,620.8 | 6,433.1 |
| Depreciation, % | 8.91 | 7.22 | 6.61 | 7.53 | 7.95 | 7.64 | 7.64 | 7.64 | 7.64 | 7.64 |
| EBIT | 4,186.0 | 7,867.0 | 10,372.0 | 8,560.0 | 7,789.0 | 10,250.7 | 11,732.1 | 13,427.6 | 15,368.2 | 17,589.2 |
| EBIT, % | 16.39 | 24.42 | 26.45 | 19.06 | 18.17 | 20.9 | 20.9 | 20.9 | 20.9 | 20.9 |
| Total Cash | 2,399.0 | 10,325.0 | 4,477.0 | 8,524.0 | 8,077.0 | 8,896.0 | 10,181.6 | 11,653.1 | 13,337.2 | 15,264.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 4,952.0 | 6,472.0 | 8,945.0 | 9,427.0 | 9,664.0 | 10,381.7 | 11,882.0 | 13,599.2 | 15,564.6 | 17,813.9 |
| Account Receivables, % | 19.39 | 20.09 | 22.81 | 20.99 | 22.55 | 21.17 | 21.17 | 21.17 | 21.17 | 21.17 |
| Inventories | 3,370.0 | 4,029.0 | 5,051.0 | 5,634.0 | 5,088.0 | 6,180.1 | 7,073.2 | 8,095.4 | 9,265.3 | 10,604.4 |
| Inventories, % | 13.19 | 12.51 | 12.88 | 12.54 | 11.87 | 12.6 | 12.6 | 12.6 | 12.6 | 12.6 |
| Accounts Payable | 1,920.0 | 2,175.0 | 2,867.0 | 3,381.0 | 2,872.0 | 3,512.9 | 4,020.5 | 4,601.6 | 5,266.6 | 6,027.7 |
| Accounts Payable, % | 7.52 | 6.75 | 7.31 | 7.53 | 6.7 | 7.16 | 7.16 | 7.16 | 7.16 | 7.16 |
| Capital Expenditure | -926.0 | -1,474.0 | -2,523.0 | -2,243.0 | -1,479.0 | -2,264.2 | -2,591.4 | -2,965.9 | -3,394.5 | -3,885.1 |
| Capital Expenditure, % | -3.63 | -4.58 | -6.43 | -4.99 | -3.45 | -4.62 | -4.62 | -4.62 | -4.62 | -4.62 |
| Tax Rate, % | 4.81 | 4.81 | 4.81 | 4.81 | 4.81 | 4.81 | 4.81 | 4.81 | 4.81 | 4.81 |
| EBITAT | 3,801.3 | 6,941.5 | 9,062.7 | 7,593.1 | 7,414.3 | 9,232.1 | 10,566.3 | 12,093.4 | 13,841.1 | 15,841.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -1,249.7 | 5,868.5 | 6,328.7 | 8,180.1 | 9,141.3 | 9,548.2 | 10,380.1 | 11,880.2 | 13,597.1 | 15,562.1 |
| WACC, % | 7.58 | 7.57 | 7.56 | 7.57 | 7.61 | 7.58 | 7.58 | 7.58 | 7.58 | 7.58 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 48,340.4 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 16,185 | |||||||||
| Terminal Value | 452,390 | |||||||||
| Present Terminal Value | 313,982 | |||||||||
| Enterprise Value | 362,322 | |||||||||
| Net Debt | 26,840 | |||||||||
| Equity Value | 335,482 | |||||||||
| Diluted Shares Outstanding, MM | 388 | |||||||||
| Equity Value Per Share | 864.64 |
What You Will Get
- Comprehensive TMO Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Instant Calculations: Intrinsic value and NPV are dynamically computed for your convenience.
- Scenario Analysis: Evaluate various scenarios to assess Thermo Fisher's future performance.
- User-Friendly Design: Crafted for professionals while remaining approachable for newcomers.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Thermo Fisher Scientific Inc. (TMO).
- WACC Calculator: Pre-designed Weighted Average Cost of Capital sheet with adjustable inputs specific to the needs of Thermo Fisher.
- Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates to fit Thermo Fisher's financial outlook.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to Thermo Fisher Scientific Inc. (TMO).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Thermo Fisher Scientific's pre-filled financial data and forecasts.
- Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you adjust your assumptions.
- Step 5: Analyze the outputs and utilize the results for your investment decisions.
Why Choose This Calculator for Thermo Fisher Scientific Inc. (TMO)?
- Precision: Utilizes accurate financial data from Thermo Fisher to ensure reliability.
- Adaptability: Crafted to allow users to easily adjust and experiment with inputs.
- Efficiency: Eliminate the need to create a DCF model from the ground up.
- Expert-Level: Designed with the expertise and usability expected by CFOs.
- Intuitive: Simple to navigate, making it accessible for users without deep financial modeling skills.
Who Should Use This Product?
- Life Science Researchers: Utilize advanced tools to analyze experimental data and enhance research outcomes.
- Healthcare Professionals: Integrate cutting-edge technologies into clinical practices for improved patient care.
- Pharmaceutical Companies: Streamline drug development processes and optimize research strategies with real-time analytics.
- Laboratory Technicians: Enhance laboratory efficiency with customizable workflows and automated solutions.
- Academic Institutions: Incorporate innovative methodologies into teaching and research programs.
What the Template Contains
- Preloaded TMO Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.